Tisotumab vedotin
Based on 1 Customer Validation
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.87%
- CAS. Nr.: 1418731-10-8
- Molecular Weight:152000 (average)
-
Speicherung:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-132258A
Mirvetuximab soravtansine (solution)ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC
Biologische Aktivität
Beschreibung
IC50 & Target
tissue factor[1].
In Vitro
Tisotumab vedotin induces immunogenic cell death in tumor cells expressing TF, leading to the release of endoplasmic reticulum stress markers, ATP, and high mobility histone B1 (HMGB1)[1]. Tisotumab vedotin induces anti-tumor activity through MMAE mediated cytotoxicity, Fc mediated antibody dependent cell phagocytosis (ADCP), and Fab mediated protease activated receptor 2 (PAR-2) signaling inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HPAF-II, SCID mice[4].
-
Dosage:2 mg/kg
-
Administration:Once daily; 25 days
-
Result:Decreased the tumor volume over the 3-week window.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1418731-10-8
-
Appearance Liquid
-
Molecular Weight 152000 (average)
-
Color Colorless to light yellow
-
SMILES
[Tisotumab vedotin]
-
Versand
Shipping with dry ice.
-
Speicherung
-80°C, protect from light
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[3]. Luu K, et al. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin. J Oncol Pharm Pract. 2023 Mar;29(2):441-449. [Content Brief]
[4]. Rubahamya B, et al. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024 May 31;10(22):eadk1894. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Tisotumab vedotin Related Classifications
HY-152963 Related Classifications
Powered by Bioz